✨ Medicines Distribution Consents




NEW ZEALAND GAZETTE

No. 204

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)

dextromethorphan hydrobromide 10 mg
Night capsule: paracetamol 500 mg, chlorpheniramine maleate 2 mg, dextromethorphan hydrobromide 10 mg | | |
Didanosine 25 mg, 50 mg, 100 mg, 150 mg | Tablets | Bristol-Myers Squibb Co., Evansville, Indiana, United States of America | Videx
Didanosine 45 mg, 67 mg, 100 mg, 167 mg, 250 mg, 375 mg | Buffered powder for oral solution | Bristol-Myers Squibb Co., Evansville, Indiana, United States of America | Videx
Tripolidine hydrochloride 1.25 mg, pseudoephedrine hydrochloride 30 mg, guaiphenesin 100 mg per 5 ml | Syrup | Wellcome Australia Limited, Cabarita, Sydney, Australia | Actifed CC Chesty
Zidovudine 100 mg, 250 mg | Capsules | Wellcome Foundation Limited, Temple Hill, Dartford, Kent, England | Retrovir
Zidovudine 200 mg/10 ml | Solution for injection | Wellcome Foundation Limited, Temple Hill, Dartford, Kent, England | Retrovir IV
Lamotrigine 25 mg, 50 mg, 100 mg | Tablets | Wellcome Foundation Limited, Temple Hill, Dartford, Kent, England | Lamictal
Nifedipine 20 mg, 50 mg | Slow release tablets | Elan Corporation Plc., Monksland, Athlone, Co Westmeath, Ireland | Unidipin
Nimodipine 30 mg | Tablets | Bayer AG, Leverkusen, Germany | Nimotop
Nimodipine 10 mg/50 ml | Infusion solution | Bayer AG, Leverkusen, Germany | Nimotop
Meglumine diatrizoate 66% w/v, sodium diatrizoate 10% w/v | Solution | Mallinckrodt Medical Inc., Raleigh, North Carolina, United States of America | MD-Gastroview

Dated this 13th day of December 1992.

C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of June 1991.
go11422

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Permethrin 5% w/w Dermal cream Burroughs Wellcome & Co, Greenville, North Carolina, United States of America Lyclear
Anhydrous dextrose 1.62 gm, potassium chloride 0.186 gm, sodium chloride 0.117 gm, citric acid anhydrous 0.384 gm, sodium bicarbonate 0.336 gm Effervescent tablets (lemon/lime and blackcurrant flavours) Woelm Pharma GmbH, Eschwege, Germany Gastrolyte Effervescent
Human recombinant erythropoietin 2000 U/ml, 4000 U/ml, 10000 U/ml Solution for injection Ortho Biologics Inc., Bo Campo Alegre, Manati, Puerto Rico Eprex
Buserelin 0.1 mg per spray Nasal spray Hoechst AG, Frankfurt am Main, Germany Suprefact

Dated this 13th day of December 1992.

C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of June 1991.
go11423

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Zalcitabine 0.375 mg, 0.75 mg Tablets Hoffman-La Roche Limited, Nutley, New Jersey, United States of America Hivid


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1992, No 204


NZLII PDF NZ Gazette 1992, No 204





✨ LLM interpretation of page content

πŸ₯ Consent to Distribution of New Medicines

πŸ₯ Health & Social Welfare
13 December 1992
Medicines, Distribution consent, Dextromethorphan, Didanosine, Tripolidine, Zidovudine, Lamotrigine, Nifedipine, Nimodipine, Meglumine diatrizoate
  • C. Loveace, Director-General of Health

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
13 December 1992
Medicines, Distribution consent, Permethrin, Dextrose, Erythropoietin, Buserelin
  • C. Loveace, Director-General of Health

πŸ₯ Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
13 December 1992
Medicines, Provisional distribution consent, Zalcitabine
  • C. Loveace, Director-General of Health